• Abivax closed an underwritten public offering of 7,360,000 ADSs, including full exercise of the underwriters’ option.
• Gross proceeds totaled about $920 million; estimated net proceeds about $874.1 million.
• Net proceeds, combined with existing cash and cash equivalents, expected to fund operations into the fourth quarter of 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.